StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Goldman Sachs Reiterates Buy Rating on Biogen (BIIB)
October 30, 2024 4:37 PM
Goldman Sachs analyst Salveen Richter reiterated a Buy rating and $290.00 price target on Biogen (NASDAQ: BIIB).The analyst comments "BIIB ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Next Articles
Biogen (BIIB) PT Lowered to $260 at RBC Capital
October 31, 2024 6:31 AM
Biogen (BIIB) PT Raised to $315 at Piper Sandler
October 30, 2024 4:54 PM
Form 10-Q BIOGEN INC. For: Sep 30
October 30, 2024 4:32 PM
Biogen lifts annual profit forecast as new treatments boost earnings
October 30, 2024 8:18 AM
Biogen raises annual earnings guidance, tops Q3 estimates; shares up
October 30, 2024 7:57 AM
Form 8-K BIOGEN INC. For: Oct 30
October 30, 2024 6:56 AM
Biogen (BIIB) Tops Q3 EPS by 31c; raises guidance
October 30, 2024 6:49 AM
Stocks expected to have increasing option volume: BIIB FPN EAT MDLZ CMG EA FSLR SNAP CZR QRVO CAKE BAC FHN
October 30, 2024 4:32 AM
Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases
October 29, 2024 6:00 PM
Biogen (BIIB) Appoints Daniel Quirk, MD, as Chief Medical Officer
October 29, 2024 8:00 AM
Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer
October 29, 2024 8:00 AM
Truist Securities Reiterates Buy Rating on Biogen (BIIB)
October 28, 2024 8:49 AM
Biogen (BIIB) Announces CFO Retirement
October 28, 2024 8:33 AM
Michael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025
October 28, 2024 8:30 AM
BMO Capital Reiterates Outperform Rating on Biogen (BIIB)
October 28, 2024 7:44 AM
